The corner office of "Silver Lining Investments" was silent, save for the rhythmic tapping of Elias Thorne’s pen against a mahogany desk. On his monitor, a sea of red tickers flickered like a warning signal. The market was bleeding, and everyone was panicking—except Elias.
He gestured to the screen. "And then there’s . They just cleared Phase II trials for a breakthrough drug. The market is ignoring them because of the macro noise, but once that FDA approval hits, you won’t be able to touch that stock for under a hundred dollars." company stocks to buy
AI responses may include mistakes. For financial advice, consult a professional. Learn more The corner office of "Silver Lining Investments" was